FI950403A - Neurosuojaavia yhdisteitä - Google Patents

Neurosuojaavia yhdisteitä Download PDF

Info

Publication number
FI950403A
FI950403A FI950403A FI950403A FI950403A FI 950403 A FI950403 A FI 950403A FI 950403 A FI950403 A FI 950403A FI 950403 A FI950403 A FI 950403A FI 950403 A FI950403 A FI 950403A
Authority
FI
Finland
Prior art keywords
pct
sec
date
neuroprotective compounds
pub
Prior art date
Application number
FI950403A
Other languages
English (en)
Swedish (sv)
Other versions
FI113769B (fi
FI950403A0 (fi
Inventor
Todd W Butler
Bertrand Chenard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI950403A0 publication Critical patent/FI950403A0/fi
Publication of FI950403A publication Critical patent/FI950403A/fi
Application granted granted Critical
Publication of FI113769B publication Critical patent/FI113769B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI950403A 1994-01-31 1995-01-30 Neurosuojaavia kromaaniyhdisteitä FI113769B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18947994A 1994-01-31 1994-01-31
US18947994 1994-01-31

Publications (3)

Publication Number Publication Date
FI950403A0 FI950403A0 (fi) 1995-01-30
FI950403A true FI950403A (fi) 1995-08-01
FI113769B FI113769B (fi) 2004-06-15

Family

ID=22697514

Family Applications (1)

Application Number Title Priority Date Filing Date
FI950403A FI113769B (fi) 1994-01-31 1995-01-30 Neurosuojaavia kromaaniyhdisteitä

Country Status (27)

Country Link
US (1) US5744483A (fi)
EP (1) EP0741724B1 (fi)
JP (1) JP2866743B2 (fi)
CN (1) CN1048247C (fi)
AT (1) ATE183184T1 (fi)
AU (1) AU684568B2 (fi)
BR (2) BR9408506A (fi)
CA (1) CA2182101C (fi)
CO (1) CO4230161A1 (fi)
CZ (1) CZ286757B6 (fi)
DE (1) DE69420053T2 (fi)
DK (1) DK0741724T3 (fi)
EG (1) EG20672A (fi)
ES (1) ES2134361T3 (fi)
FI (1) FI113769B (fi)
GR (1) GR3031356T3 (fi)
HU (1) HU221633B1 (fi)
IL (1) IL112415A (fi)
MY (1) MY111623A (fi)
NO (1) NO309190B1 (fi)
NZ (1) NZ275151A (fi)
PE (1) PE43795A1 (fi)
PL (1) PL179448B1 (fi)
RU (1) RU2126404C1 (fi)
TW (1) TW449591B (fi)
WO (1) WO1995020587A1 (fi)
ZA (1) ZA95692B (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232059A1 (en) * 1995-09-15 1997-03-20 Bertrand Leo Chenard Phenol derivatives with pharmaceutical activity
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
WO2007051735A1 (en) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
WO2007084595A2 (en) * 2006-01-20 2007-07-26 Schering Corporation Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
EP2522647B1 (en) * 2011-05-10 2014-04-30 DSM IP Assets B.V. Process of separating chiral isomers of chroman compounds and their derivatives and precursors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (fi) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
US4082755A (en) * 1977-02-14 1978-04-04 Janssen Pharmaceutica N.V. 1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (en) * 1978-07-03 1980-02-07 Sandoz Ag 3-aminopropoxy-aryl derivates,preparation and use thereof
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) * 1980-12-04 1982-07-08 C.H. Boehringer Sohn, 6507 Ingelheim Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3274350D1 (en) * 1981-09-25 1987-01-08 Beecham Group Plc Pharmaceutically active benzopyran compounds
EP0093534A1 (en) * 1982-04-28 1983-11-09 Beecham Group Plc Novel chromanols
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) * 1989-02-07 1990-11-06 Transitions Research Corporation Dual bumper-light curtain obstacle detection sensor
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
HU222726B1 (hu) * 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
CZ286757B6 (en) 2000-06-14
PE43795A1 (es) 1995-12-09
HUT75942A (en) 1997-05-28
TW449591B (en) 2001-08-11
CO4230161A1 (es) 1995-10-19
NO963186L (no) 1996-07-30
FI113769B (fi) 2004-06-15
MY111623A (en) 2000-09-27
IL112415A0 (en) 1995-03-30
WO1995020587A1 (en) 1995-08-03
CN1142825A (zh) 1997-02-12
NO309190B1 (no) 2000-12-27
CA2182101A1 (en) 1995-08-03
HU221633B1 (hu) 2002-12-28
US5744483A (en) 1998-04-28
BR9500380A (pt) 1995-10-17
ES2134361T3 (es) 1999-10-01
EP0741724B1 (en) 1999-08-11
HU9602100D0 (en) 1996-09-30
JPH09501698A (ja) 1997-02-18
PL179448B1 (pl) 2000-09-29
AU8066394A (en) 1995-08-15
DE69420053D1 (de) 1999-09-16
EG20672A (en) 1999-11-30
ATE183184T1 (de) 1999-08-15
PL315681A1 (en) 1996-11-25
CN1048247C (zh) 2000-01-12
EP0741724A1 (en) 1996-11-13
BR9408506A (pt) 1997-08-05
DE69420053T2 (de) 1999-11-25
NZ275151A (en) 1998-02-26
GR3031356T3 (en) 2000-01-31
RU2126404C1 (ru) 1999-02-20
FI950403A0 (fi) 1995-01-30
AU684568B2 (en) 1997-12-18
IL112415A (en) 1999-07-14
ZA95692B (en) 1996-07-30
CZ225696A3 (en) 1997-01-15
JP2866743B2 (ja) 1999-03-08
DK0741724T3 (da) 1999-12-20
CA2182101C (en) 1999-08-03
NO963186D0 (no) 1996-07-30

Similar Documents

Publication Publication Date Title
ATE206611T1 (de) Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
DK0946162T3 (da) Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme
BR9408506A (pt) Compostos neuroprotetores
NO20012310D0 (no) Optisk aktiv pyridyl-4H-1,2,4-oksazdiazinderivat og dets anvendelse ved behandling av karsykdommer
ATE191342T1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
EP0653936A1 (en) USE OF 2- (4- (4-CHLOROPHENYL) CYCLOHEXYL] -3-HYDROXY-1,4-NAPHTOQUINONE IN THE TREATMENT OF CANCER.
NO20091111L (no) Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия

Legal Events

Date Code Title Description
MA Patent expired